Literature DB >> 23314689

Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes.

Pam R Taub1, Erin Higginbotham, Robert R Henry.   

Abstract

Epidemiological data demonstrates that improved regulation of blood glucose correlates with better cardiovascular (CV) outcomes. Conversely, some interventional studies have demonstrated that tight glycemic control has no benefit or can even result in worse CV outcomes. These conclusions parallel the paradox that glycemic control has proven beneficial for microvascular outcomes, while few studies have demonstrated significant macrovascular benefits. This imprecise understanding conveys the need to better comprehend the mechanisms of glycemic control and its impact on CV disease. Such variations in data also require a more comprehensive approach to diabetes and CV disease in which multiple biomarkers such as low density lipoprotein (LDL), low adiponectin, elevated C-reactive protein (CRP) and well established clinical parameters such as high blood pressure, weight, and functional status are incorporated into clinical decision making. Reliance on one parameter in isolation such as glycemic control and one biomarker such as HbA1C does not provide an accurate assessment of CV outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23314689     DOI: 10.1007/s11886-012-0332-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  66 in total

Review 1.  Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.

Authors:  Toni Terry; Kalyani Raravikar; Nalurporn Chokrungvaranon; Peter D Reaven
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

2.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

3.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

Review 4.  Comprehensive management of patients with type 2 diabetes: establishing priorities of care.

Authors:  D M Kendall; R M Bergenstal
Journal:  Am J Manag Care       Date:  2001-08       Impact factor: 2.229

Review 5.  Pre-diabetes, metabolic syndrome, and cardiovascular risk.

Authors:  Scott M Grundy
Journal:  J Am Coll Cardiol       Date:  2012-02-14       Impact factor: 24.094

6.  Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.

Authors:  T Kaiser; P T Sawicki
Journal:  Diabetologia       Date:  2004-01-16       Impact factor: 10.122

7.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

8.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

9.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

10.  Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.

Authors:  Peter D Reaven; Thomas E Moritz; Dawn C Schwenke; Robert J Anderson; Michael Criqui; Robert Detrano; Nicholas Emanuele; Moti Kayshap; Jennifer Marks; Sunder Mudaliar; R Harsha Rao; Jayendra H Shah; Steven Goldman; Domenic J Reda; Madeline McCarren; Carlos Abraira; William Duckworth
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more
  2 in total

Review 1.  Diabetes Management - Lowering Cardiovascular Risk.

Authors:  Dan Gaiţă; Svetlana Moşteoru; Laurence Sperling
Journal:  Eur Cardiol       Date:  2014-07

Review 2.  The association between diabetes and dermal microvascular dysfunction non-invasively assessed by laser Doppler with local thermal hyperemia: a systematic review with meta-analysis.

Authors:  Dagmar Fuchs; Pepijn P Dupon; Laura A Schaap; Richard Draijer
Journal:  Cardiovasc Diabetol       Date:  2017-01-19       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.